Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29286181 | 0.90 | MTNR1A (0.33) | MTNR1AMTNR1BITGA4ITGB7GABRA1 | |
| SCHEMBL29286182 | 0.90 | MTNR1A (0.33) | MTNR1AMTNR1BITGA4ITGB7GABRA1 | |
| SCHEMBL18170236 | 0.88 | AAK1 (0.39) | MTNR1AMTNR1BITGA4ITGB7 | |
| SCHEMBL30716049 | 0.82 | ITGA4 (0.37) | ITGA4ITGB7 | |
| SCHEMBL23544355 | 0.79 | SLC7A5 (0.38) | MTNR1AMTNR1BITGA4ITGB7GABRA1 | |
| SCHEMBL29286178 | 0.79 | SLC7A5 (0.38) | MTNR1AMTNR1BITGA4ITGB7GABRA1 | |
| SCHEMBL28511408 | 0.78 | AAK1 (0.39) | MTNR1AMTNR1B | |
| SCHEMBL18805055 | 0.78 | ELANE (0.39) | MTNR1AMTNR1B | |
| SCHEMBL25528806 | 0.78 | AAK1 (0.40) | MTNR1AMTNR1BITGA4ITGB7 | |
| SCHEMBL18179190 | 0.77 | AAK1 (0.39) | ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242555-A1 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | NEUBORON MEDTECH LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655261-B2 | Method for preparing 18F-BPA and intermediate | NEUBORON MEDTECH LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242555-A1 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | CYP19A1, SHBG, ESR1 | MTNR1A 1985/4885MTNR1B 2036/4885ITGA4 3738/4885 |
| US-11655261-B2 | Method for preparing 18F-BPA and intermediate | CYP19A1, SHBG, ESR1 | MTNR1A 1985/4885MTNR1B 2036/4885ITGA4 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.